PURPOSE: Release of inhibitory coregulatory proteins into the circulation may represent one mechanism by which tumors thwart immune responses. Our objective was to determine whether soluble B7-H1 (sB7-H1) levels in patients with clear cell renal cell carcinoma (ccRCC) are associated with pathologic features and patient outcome. EXPERIMENTAL DESIGN: We developed an ELISA for quantification of sB7-H1 in biological fluids. Biochemical confirmation of the measured analyte as sB7-H1 was done by protein microsequencing using supernates from tumor cell lines. Biological activity of sB7-H1 was assessed in vitro utilizing T-cell apoptosis assays. We tested sB7-H1 levels in the sera from 172 ccRCC patients and correlated sB7-H1 levels with pathologic features and patient outcome. RESULTS: sB7-H1 was detected in the cell supernatants of some B7-H1-positive tumor cell lines. Protein sequencing established that the measured sB7-H1 retained its receptor-binding domain and could deliver proapoptotic signals to T cells. Higher preoperative sB7-H1 levels were associated with larger tumors (P < 0.001), tumors of advanced stage (P = 0.017) and grade (P = 0.044), and tumors with necrosis (P = 0.003). A doubling of sB7-H1 levels was associated with a 41% increased risk of death (P = 0.010). CONCLUSION: Our observations suggest that sB7-H1 may be detected in the sera of ccRCC patients and that sB7-H1 may systemically impair host immunity, thereby fostering cancer progression and subsequent poor clinical outcome.
PURPOSE: Release of inhibitory coregulatory proteins into the circulation may represent one mechanism by which tumors thwart immune responses. Our objective was to determine whether soluble B7-H1 (sB7-H1) levels in patients with clear cell renal cell carcinoma (ccRCC) are associated with pathologic features and patient outcome. EXPERIMENTAL DESIGN: We developed an ELISA for quantification of sB7-H1 in biological fluids. Biochemical confirmation of the measured analyte as sB7-H1 was done by protein microsequencing using supernates from tumor cell lines. Biological activity of sB7-H1 was assessed in vitro utilizing T-cell apoptosis assays. We tested sB7-H1 levels in the sera from 172 ccRCC patients and correlated sB7-H1 levels with pathologic features and patient outcome. RESULTS:sB7-H1 was detected in the cell supernatants of some B7-H1-positive tumor cell lines. Protein sequencing established that the measured sB7-H1 retained its receptor-binding domain and could deliver proapoptotic signals to T cells. Higher preoperative sB7-H1 levels were associated with larger tumors (P < 0.001), tumors of advanced stage (P = 0.017) and grade (P = 0.044), and tumors with necrosis (P = 0.003). A doubling of sB7-H1 levels was associated with a 41% increased risk of death (P = 0.010). CONCLUSION: Our observations suggest that sB7-H1 may be detected in the sera of ccRCC patients and that sB7-H1 may systemically impair host immunity, thereby fostering cancer progression and subsequent poor clinical outcome.
Authors: M S Pepe; R Etzioni; Z Feng; J D Potter; M L Thompson; M Thornquist; M Winget; Y Yasui Journal: J Natl Cancer Inst Date: 2001-07-18 Impact factor: 13.506
Authors: M Hebbar; P Jeannin; G Magistrelli; P-Y Hatron; E Hachulla; B Devulder; J-Y Bonnefoy; Y Delneste Journal: Clin Exp Immunol Date: 2004-05 Impact factor: 4.330
Authors: Igor Frank; Michael L Blute; John C Cheville; Christine M Lohse; Amy L Weaver; Horst Zincke Journal: J Urol Date: 2002-12 Impact factor: 7.450
Authors: Haidong Dong; Scott E Strome; Diva R Salomao; Hideto Tamura; Fumiya Hirano; Dallas B Flies; Patrick C Roche; Jun Lu; Gefeng Zhu; Koji Tamada; Vanda A Lennon; Esteban Celis; Lieping Chen Journal: Nat Med Date: 2002-06-24 Impact factor: 53.440
Authors: Douglas C Parker; Andrew L Folpe; Julie Bell; Esther Oliva; Robert H Young; Cynthia Cohen; Mahul B Amin Journal: Am J Surg Pathol Date: 2003-01 Impact factor: 6.394
Authors: Stephan Kruger; Marie-Louise Legenstein; Verena Rösgen; Michael Haas; Dominik Paul Modest; Christoph Benedikt Westphalen; Steffen Ormanns; Thomas Kirchner; Volker Heinemann; Stefan Holdenrieder; Stefan Boeck Journal: Oncoimmunology Date: 2017-03-31 Impact factor: 8.110
Authors: Alexander W MacFarlane; Mowafaq Jillab; Elizabeth R Plimack; Gary R Hudes; Robert G Uzzo; Samuel Litwin; Essel Dulaimi; Tahseen Al-Saleem; Kerry S Campbell Journal: Cancer Immunol Res Date: 2013-11-25 Impact factor: 11.151
Authors: Jun Zhou; Kathleen M Mahoney; Anita Giobbie-Hurder; Fengmin Zhao; Sandra Lee; Xiaoyun Liao; Scott Rodig; Jingjing Li; Xinqi Wu; Lisa H Butterfield; Matthias Piesche; Michael P Manos; Lauren M Eastman; Glenn Dranoff; Gordon J Freeman; F Stephen Hodi Journal: Cancer Immunol Res Date: 2017-05-18 Impact factor: 11.151
Authors: Nadia B Hassounah; Venkat S Malladi; Yi Huang; Samuel S Freeman; Ellen M Beauchamp; Shohei Koyama; Nicholas Souders; Sunil Martin; Glenn Dranoff; Kwok-Kin Wong; Chandra S Pedamallu; Peter S Hammerman; Esra A Akbay Journal: Cancer Immunol Immunother Date: 2018-12-18 Impact factor: 6.968